Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of Probiotics in Adults With Irritable Bowel Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Otherwise well and meet the criteria for IBS as defined by the Rome III criteria~* Ability to speak and understand English~* Telephone access~* IBS Severity Scale score of \>= 75~Exclusion Criteria:~* Organic disease accounting for GI symptoms.~* Chronic illness such as renal disease, congenital heart disease, diabetes, moderate or severe asthma, abdominal surgery, or immunosuppressed (e.g., organ transplant recipient).~* Have received extraneous probiotic (i.e., not in a food such as yogurt) within 4 months of starting the study.~* Subjects who are taking prescription or over-the-counter medications for GI disorders that completely relieve their symptoms because by definition these individuals do not have IBS (e.g., antacids, proton pump inhibitors, histamine receptor antagonists).~* Medication allergies or contraindications which would preclude antimicrobial treatment for potential infection with VSL#3 component organisms.~* Pregnancy.~* Subjects who have an individual in the household who is immunosuppressed (e.g., genetic immune disorder, organ transplant).~* Oral temperature \> 38.0 degrees Celsius.~* Poorly controlled hypertension, history of cardiac disease, stroke/cerebral vascular accident, bowel ischemia, or other risk factors for bowel ischemia.~* History of acute or chronic pancreatitis~* Cardiac valvular disease or other risk factor for endocarditis~* Subjects who indicate on the IBS scoring questionnaire that their pain is severe or very severe.~* Subjects who pain lasts more than 5 out of 10 days.~* Subjects whose scores indicate more than mild IBS who are over 45 years of age

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Probiotic (Type: EXPERIMENTAL): To determine the safety and effectiveness of the probiotic VSL#3 in adults with irritable bowel syndrome (IBS).

Based on this trial design, predict the completion outcome and termination type (if applicable).